Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

MAPK pathway and B cells overactivation in multiple sclerosis revealed by phosphoproteomics and genomic analysis.

Kotelnikova E, Kiani NA, Messinis D, Pertsovskaya I, Pliaka V, Bernardo-Faura M, Rinas M, Vila G, Zubizarreta I, Pulido-Valdeolivas I, Sakellaropoulos T, Faigle W, Silberberg G, Masso M, Stridh P, Behrens J, Olsson T, Martin R, Paul F, Alexopoulos LG, Saez-Rodriguez J, Tegner J, Villoslada P.

Proc Natl Acad Sci U S A. 2019 May 7;116(19):9671-9676. doi: 10.1073/pnas.1818347116. Epub 2019 Apr 19.

PMID:
31004050
2.

Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial.

Zubizarreta I, Flórez-Grau G, Vila G, Cabezón R, España C, Andorra M, Saiz A, Llufriu S, Sepulveda M, Sola-Valls N, Martinez-Lapiscina EH, Pulido-Valdeolivas I, Casanova B, Martinez Gines M, Tellez N, Oreja-Guevara C, Español M, Trias E, Cid J, Juan M, Lozano M, Blanco Y, Steinman L, Benitez-Ribas D, Villoslada P.

Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8463-8470. doi: 10.1073/pnas.1820039116. Epub 2019 Apr 8.

3.

Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation.

Villoslada P, Vila G, Colafrancesco V, Moreno B, Fernandez-Diez B, Vazquez R, Pertsovskaya I, Zubizarreta I, Pulido-Valdeolivas I, Messeguer J, Vendrell-Navarro G, Frade JM, López-Sánchez N, Teixido M, Giralt E, Masso M, Dugas JC, Leonoudakis D, Lariosa-Willingham KD, Steinman L, Messeguer A.

Neurotherapeutics. 2019 Feb 27. doi: 10.1007/s13311-019-00717-4. [Epub ahead of print]

PMID:
30815844
4.

Disease duration and disability in dysfeRlinopathy can be described by muscle imaging using heatmaps and random forests.

Gómez-Andrés D, Díaz J, Munell F, Sánchez-Montáñez Á, Pulido-Valdeolivas I, Suazo L, Garrido C, Quijano-Roy S, Bevilacqua JA.

Muscle Nerve. 2019 Apr;59(4):436-444. doi: 10.1002/mus.26403. Epub 2019 Jan 10.

PMID:
30578674
5.

Spanish validation of the telephone assessed Expanded Disability Status Scale and Patient Determined Disease Steps in people with multiple sclerosis.

Solà-Valls N, Vicente-Pascual M, Blanco Y, Solana E, Llufriu S, Martínez-Heras E, Martínez-Lapiscina EH, Sepúlveda M, Pulido-Valdeolivas I, Zubizarreta I, Saiz A.

Mult Scler Relat Disord. 2019 Jan;27:333-339. doi: 10.1016/j.msard.2018.11.018. Epub 2018 Nov 19.

PMID:
30472411
6.

Magnetic resonance markers of tissue damage related to connectivity disruption in multiple sclerosis.

Solana E, Martinez-Heras E, Martinez-Lapiscina EH, Sepulveda M, Sola-Valls N, Bargalló N, Berenguer J, Blanco Y, Andorra M, Pulido-Valdeolivas I, Zubizarreta I, Saiz A, Llufriu S.

Neuroimage Clin. 2018 Jul 12;20:161-168. doi: 10.1016/j.nicl.2018.07.012. eCollection 2018.

7.

Muscle imaging in laminopathies: Synthesis study identifies meaningful muscles for follow-up.

GóMez-Andrés D, Díaz-Manera J, Alejaldre A, Pulido-Valdeolivas I, GonzáLez-Mera L, Olivé M, Vilchez JJ, De Munain AL, Paradas C, Muelas N, SáNchez-MontáÑez Á, Alonso-Jimenez A, De la Banda MGG, Dabaj I, Bonne G, Munell F, Carlier RY, Quijano-Roy S.

Muscle Nerve. 2018 Dec;58(6):812-817. doi: 10.1002/mus.26312. Epub 2018 Nov 18.

PMID:
30066418
8.

Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine.

Sola-Valls N, Blanco Y, Sepúlveda M, Llufriu S, Martínez-Lapiscina EH, Zubizarreta I, Pulido-Valdeolivas I, Montejo C, Villoslada P, Saiz A.

Ther Adv Neurol Disord. 2018 Jun 10;11:1756286418780007. doi: 10.1177/1756286418780007. eCollection 2018.

9.

Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis.

Andorra M, Nakamura K, Lampert EJ, Pulido-Valdeolivas I, Zubizarreta I, Llufriu S, Martinez-Heras E, Sola-Valls N, Sepulveda M, Tercero-Uribe A, Blanco Y, Saiz A, Villoslada P, Martinez-Lapiscina EH.

JAMA Neurol. 2018 Oct 1;75(10):1246-1255. doi: 10.1001/jamaneurol.2018.1596.

PMID:
29971335
10.

Predictors of vision impairment in Multiple Sclerosis.

Sanchez-Dalmau B, Martinez-Lapiscina EH, Pulido-Valdeolivas I, Zubizarreta I, Llufriu S, Blanco Y, Sola-Valls N, Sepulveda M, Guerrero A, Alba S, Andorra M, Camos A, Sanchez-Vela L, Alfonso V, Saiz A, Villoslada P.

PLoS One. 2018 Apr 17;13(4):e0195856. doi: 10.1371/journal.pone.0195856. eCollection 2018.

11.

Gait phenotypes in paediatric hereditary spastic paraplegia revealed by dynamic time warping analysis and random forests.

Pulido-Valdeolivas I, Gómez-Andrés D, Martín-Gonzalo JA, Rodríguez-Andonaegui I, López-López J, Pascual-Pascual SI, Rausell E.

PLoS One. 2018 Mar 8;13(3):e0192345. doi: 10.1371/journal.pone.0192345. eCollection 2018.

12.

Dynamics and heterogeneity of brain damage in multiple sclerosis.

Kotelnikova E, Kiani NA, Abad E, Martinez-Lapiscina EH, Andorra M, Zubizarreta I, Pulido-Valdeolivas I, Pertsovskaya I, Alexopoulos LG, Olsson T, Martin R, Paul F, Tegnér J, Garcia-Ojalvo J, Villoslada P.

PLoS Comput Biol. 2017 Oct 26;13(10):e1005757. doi: 10.1371/journal.pcbi.1005757. eCollection 2017 Oct.

13.

Early retinal atrophy predicts long-term visual impairment after acute optic neuritis.

Sanchez-Dalmau B, Martinez-Lapiscina EH, Torres-Torres R, Ortiz-Perez S, Zubizarreta I, Pulido-Valdeolivas IV, Alba-Arbalat S, Guerrero-Zamora A, Calbet D, Villoslada P.

Mult Scler. 2018 Aug;24(9):1196-1204. doi: 10.1177/1352458517718628. Epub 2017 Jul 3.

PMID:
28669275
14.

Metabolomic signatures associated with disease severity in multiple sclerosis.

Villoslada P, Alonso C, Agirrezabal I, Kotelnikova E, Zubizarreta I, Pulido-Valdeolivas I, Saiz A, Comabella M, Montalban X, Villar L, Alvarez-Cermeño JC, Fernández O, Alvarez-Lafuente R, Arroyo R, Castro A.

Neurol Neuroimmunol Neuroinflamm. 2017 Jan 27;4(2):e321. doi: 10.1212/NXI.0000000000000321. eCollection 2017 Mar.

15.

Patterns of motor signs in spinocerebellar ataxia type 3 at the start of follow-up in a reference unit.

Pulido-Valdeolivas I, Gómez-Andrés D, Sanz-Gallego I, Rausell E, Arpa J.

Cerebellum Ataxias. 2016 Feb 23;3:4. doi: 10.1186/s40673-016-0042-6. eCollection 2016.

16.

Putamina involvement in Wernicke encephalopathy induced by Janus Kinase 2 inhibitor.

Rodríguez-Pardo J, Puertas-Muñoz I, Martínez-Sánchez P, Díaz de Terán J, Pulido-Valdeolivas I, Fuentes B.

Clin Neuropharmacol. 2015 May-Jun;38(3):117-8. doi: 10.1097/WNF.0000000000000083.

PMID:
25970282
17.

Substantia nigra echogenicity in hereditary ataxias with and without nigrostriatal pathology: a pilot study.

Martínez-Sánchez P, Cazorla-García R, Sanz-Gallego I, Correas-Callero E, Pulido-Valdeolivas I, Arpa J.

Cerebellum. 2015 Jun;14(3):240-6. doi: 10.1007/s12311-014-0642-8.

PMID:
25592070
18.

Abnormal motor phenotype at adult stages in mice lacking type 2 deiodinase.

Bárez-López S, Bosch-García D, Gómez-Andrés D, Pulido-Valdeolivas I, Montero-Pedrazuela A, Obregon MJ, Guadaño-Ferraz A.

PLoS One. 2014 Aug 1;9(8):e103857. doi: 10.1371/journal.pone.0103857. eCollection 2014.

19.

[External evaluation of gait and functional changes after a single-session multiple myofibrotenotomy in school-aged children with spastic diplegia].

Gómez-Andrés D, Pulido-Valdeolivas I, Martín-Gonzalo JA, López-López J, Martínez-Caballero I, Gómez-Barrena E, Rausell E.

Rev Neurol. 2014 Mar 16;58(6):247-54. Spanish.

Supplemental Content

Loading ...
Support Center